Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

MAPK7 and MAP2K4 as prognostic markers in osteosarcoma.

Tesser-Gamba F, Petrilli AS, de Seixas Alves MT, Filho RJ, Juliano Y, Toledo SR.

Hum Pathol. 2012 Jul;43(7):994-1002. doi: 10.1016/j.humpath.2011.08.003. Epub 2011 Dec 9.

PMID:
22154052
2.

Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma.

Wang Z, Cai H, Lin L, Tang M, Cai H.

Pediatr Blood Cancer. 2014 Feb;61(2):206-10. doi: 10.1002/pbc.24763. Epub 2013 Sep 9.

PMID:
24038809
3.

Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents.

Buddingh EP, Kuijjer ML, Duim RA, Bürger H, Agelopoulos K, Myklebost O, Serra M, Mertens F, Hogendoorn PC, Lankester AC, Cleton-Jansen AM.

Clin Cancer Res. 2011 Apr 15;17(8):2110-9. doi: 10.1158/1078-0432.CCR-10-2047. Epub 2011 Mar 3.

4.

Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy.

Sadikovic B, Thorner P, Chilton-Macneill S, Martin JW, Cervigne NK, Squire J, Zielenska M.

BMC Cancer. 2010 May 13;10:202. doi: 10.1186/1471-2407-10-202.

5.

Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma.

Dalla-Torre CA, Yoshimoto M, Lee CH, Joshua AM, de Toledo SR, Petrilli AS, Andrade JA, Chilton-MacNeill S, Zielenska M, Squire JA.

BMC Cancer. 2006 Oct 5;6:237.

6.

Aberrant expression of the human epidermal growth factor receptor 2 oncogene is not a common feature in osteosarcoma.

Baumhoer D, Smida J, Specht K, Bink K, Quintanilla-Martinez L, Rosemann M, Siggelkow H, Nathrath WB, Atkinson MJ, Bielack S, Jundt G, Nathrath M.

Hum Pathol. 2011 Jun;42(6):859-66. doi: 10.1016/j.humpath.2010.09.016. Epub 2011 Feb 2.

PMID:
21292304
7.

Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.

Caronia D, Patiño-García A, Milne RL, Zalacain-Díez M, Pita G, Alonso MR, Moreno LT, Sierrasesumaga-Ariznabarreta L, Benítez J, González-Neira A.

Pharmacogenomics J. 2009 Oct;9(5):347-53. doi: 10.1038/tpj.2009.19. Epub 2009 May 12.

PMID:
19434073
8.

The metastatic behavior of osteosarcoma by gene expression and cytogenetic analyses.

Salinas-Souza C, De Oliveira R, Alves MT, Garcia Filho RJ, Petrilli AS, Toledo SR.

Hum Pathol. 2013 Oct;44(10):2188-98. doi: 10.1016/j.humpath.2013.04.013. Epub 2013 Jul 8.

PMID:
23845465
9.

Expression profiles of osteosarcoma that can predict response to chemotherapy.

Man TK, Chintagumpala M, Visvanathan J, Shen J, Perlaky L, Hicks J, Johnson M, Davino N, Murray J, Helman L, Meyer W, Triche T, Wong KK, Lau CC.

Cancer Res. 2005 Sep 15;65(18):8142-50.

10.

Amplification of 17p11.2 approximately p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma.

van Dartel M, Cornelissen PW, Redeker S, Tarkkanen M, Knuutila S, Hogendoorn PC, Westerveld A, Gomes I, Bras J, Hulsebos TJ.

Cancer Genet Cytogenet. 2002 Dec;139(2):91-6.

PMID:
12550767
11.

Prognostic value of CCN3 in osteosarcoma.

Perbal B, Zuntini M, Zambelli D, Serra M, Sciandra M, Cantiani L, Lucarelli E, Picci P, Scotlandi K.

Clin Cancer Res. 2008 Feb 1;14(3):701-9. doi: 10.1158/1078-0432.CCR-07-0806.

12.
13.

MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study.

Wunder JS, Bull SB, Aneliunas V, Lee PD, Davis AM, Beauchamp CP, Conrad EU, Grimer RJ, Healey JH, Rock MJ, Bell RS, Andrulis IL.

J Clin Oncol. 2000 Jul;18(14):2685-94.

PMID:
10894867
14.

Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data.

Kuijjer ML, Rydbeck H, Kresse SH, Buddingh EP, Lid AB, Roelofs H, Bürger H, Myklebost O, Hogendoorn PC, Meza-Zepeda LA, Cleton-Jansen AM.

Genes Chromosomes Cancer. 2012 Jul;51(7):696-706. doi: 10.1002/gcc.21956. Epub 2012 Mar 27.

PMID:
22454324
15.

Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma.

Cai H, Lin L, Cai H, Tang M, Wang Z.

Med Oncol. 2013 Jun;30(2):499. doi: 10.1007/s12032-013-0499-6. Epub 2013 Feb 22.

PMID:
23430441
16.

C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression.

Gamberi G, Benassi MS, Bohling T, Ragazzini P, Molendini L, Sollazzo MR, Pompetti F, Merli M, Magagnoli G, Balladelli A, Picci P.

Oncology. 1998 Nov-Dec;55(6):556-63.

PMID:
9778623
17.

Relationship between P-glycoprotein expression and p53 status in high-grade osteosarcoma.

Serra M, Maurici D, Scotlandi K, Barbanti-Brodano G, Manara MC, Benini S, Picci P, Bertoni F, Bacci G, Sottili S, Baldini N.

Int J Oncol. 1999 Feb;14(2):301-7.

PMID:
9917506
18.

Prognostic significance of drug-regulated genes in high-grade osteosarcoma.

Fellenberg J, Bernd L, Delling G, Witte D, Zahlten-Hinguranage A.

Mod Pathol. 2007 Oct;20(10):1085-94. Epub 2007 Jul 27.

19.

HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study.

Somers GR, Ho M, Zielenska M, Squire JA, Thorner PS.

Pediatr Dev Pathol. 2005 Sep-Oct;8(5):525-32. Epub 2005 Oct 5.

PMID:
16211448
20.

ErbB2 expression is correlated with increased survival of patients with osteosarcoma.

Akatsuka T, Wada T, Kokai Y, Kawaguchi S, Isu K, Yamashiro K, Yamashita T, Sawada N, Yamawaki S, Ishii S.

Cancer. 2002 Mar 1;94(5):1397-404.

Items per page

Supplemental Content

Write to the Help Desk